GlassScriptPhysician profile
Steven Nguyen
NPI 1124631619
$8,328.41
in general payments reported to CMS, 2019-2025
26 companies · $1,155 in 2025
The $1,155 reported for 2025 was more than what 85% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,199 · 2022: $2,151 · 2023: $1,606 · 2024: $1,218 · 2025: $1,155.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,978.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,978.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $1,497.18 | 2021-2025 | Qelbree, Qelbree |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,416.59 | 2021-2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $1,281.69 | 2021-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Abbvie INC. | $1,225.56 | 2021-2025 | |
| Alkermes, INC. | $338.62 | 2021-2025 | Aristada, Lybalvi |
| Neurocrine Biosciences, INC. | $336.82 | 2021-2025 | Ingrezza |
| Takeda Pharmaceuticals U.S.A., INC. | $314.63 | 2021-2025 | Trintellix |
| Lundbeck LLC | $291.32 | 2021-2025 | Rexulti |
| Janssen Pharmaceuticals, INC | $260.75 | 2021-2025 | Spravato |
| Teva Pharmaceuticals USA, INC. | $252.90 | 2021-2023 | Uzedy |
| Axsome Therapeutics, INC. | $195.66 | 2022-2025 | Auvelity |
| E.R. Squibb & Sons, L.L.C. | $178.77 | 2025 | Cobenfy |
| Corium, LLC | $135.11 | 2022-2025 | Azstarys |
| Vanda Pharmaceuticals INC. | $99.09 | 2024-2025 | Fanapt |
| Neos Therapeutics, LP | $74.15 | 2021-2024 | Adzenys Xr-Odt, Cotempla Xr-Odt |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ironshore Pharmaceuticals INC. | $58.91 | 2022-2024 | Jornay Pm |
| Avanir Pharmaceuticals, INC. | $56.11 | 2021-2022 | |
| Orexo US, INC. | $49.79 | 2021 | |
| Idorsia Pharmaceuticals US INC | $45.22 | 2023 | Quviviq |
| Indivior INC. | $44.41 | 2024 | Perseris |
| Owp Pharmaceuticals, INC. | $40.39 | 2021-2023 | Subvenite, Lamotrigine |
| Almatica Pharma LLC | $35.89 | 2022 | |
| Adlon Therapeutics L.P. | $34.62 | 2021 | |
| Sunovion Pharmaceuticals INC. | $27.15 | 2021 | |
| Tris Pharma INC | $23.33 | 2025 | Dyanavel Xr |
| Eisai INC. | $13.75 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steven Nguyen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.